-5.5 | | Pax7 | '70 week' vs '6 week' in 'none; none; | age, irradiate | Pericyte induced reprogramming of the bone marrow microenvironment drives stem and cancer cell quiescence |
-5.2 | | Pax7 | 'osteosarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-4.2 | | Pax7 | 'clear cell sarcoma; TATCre' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
4.1 | | Pax7 | 'AZD7507; AZD5069 (at same dosage); 100 milligram per kilogram' vs 'none' | compound | RNA-seq to investigate differentially expressed genes in KPC mouse PDAC treated with CSF-1R small molecule inhibitor AZD7507 and/or the CXCR2 small molecule inhibitor AZD5069 |
4 | | Pax7 | 'extraembryonic endoderm stem cell; grown in XEN cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
3.8 | | Pax7 | 'doxorubicin; 17.5 milligram per kilogram body weight' vs 'vehicle' in 'scramble; podocyte' | cell type, compound, genotype | Transcription profiling to identify the role of MOF in primary MEFs and differentiated podocytes in response to Adriamycin |
-3.6 | | Pax7 | 'clear cell sarcoma; Rosa26CreER' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
3.2 | | Pax7 | 'synovial sarcoma' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
2.6 | | Pax7 | 'synovial sarcoma' vs 'normal' | disease | Transcription profiling by array of tumors excised from conditional mouse model of synovial sarcoma compared to skeletal muscle from wild type mice |
2.5 | | Pax7 | 'stabilization-competent' vs 'stabilization-incompetent' in '23 day; secondary reprogramming cell' | age, cell type, phenotype | Transcription profiling by high throughput sequencing in gene expresion profile of 4 SC clones and 4 SI clones at different time points defined a stabilization competency signiture |
2.4 | | Pax7 | 'etoposide; 2.5 micromolar' vs 'none' in 'wild type genotype' | compound, genotype | RNA-seq of H2afj-ko and isogenic WT C57/Bl6-N mouse embryonic fibroblasts in proliferation and after etoposide-induced senescence. |
2.2 | | Pax7 | 'Triple knockout (Zfp36-/-, TNFR1-/-, TNFR2-/-)' vs 'wild type' | genotype | Transcription profiling by high throughput sequencing of douple (TNFR1-/-/TNFR2-/-) and triple (Zfp36-/-/TNFR1-/-/TNFR2-/-) knockout mouse spleens |
-2 | | Pax7 | 'no limb muscle' vs 'wild type' | phenotype | Transcription profiling by array of TS23 humerus tissue from muscle-less mutant (splotch-delayed) mice and control littermates to identify differentially expressed genes between muscle-less and control embryonic (TS23) humerus tissue, in order to determine mechanosensitive genes that impact skeletal development |
-1.9 | | Pax7 | 'Sall4 homozygous knockout' vs 'wild type genotype' | genotype | RNA-Seq of Sall4 mutants in mouse embryonic stem cells |
-1.8 | | Pax7 | '129S1 allele at SNP rs50454566' vs 'wild type genotype' | genotype | RNA-Seq of mouse embryonic stem cells derived from genetically diverse inbred mouse strains with varying alleles at Lifr gene |
-1.8 | | Pax7 | 'XBP1s overexpression' vs 'wild type genotype' in '4μ8C; 15 micromolar' | compound, genotype | Overexpression of spliced XBP1 in in vitro Th2 cells, and comparison to 4u8c treatment |
-1.6 | | Pax7 | 'Mettl6 knockout clone D1' vs 'wild type genotype' | genotype | METTL6 is a tRNA m3C methyltransferase that regulates translation and tumor cell proliferation |
-1.4 | | Pax7 | 'pre-B acute lymphoblastic leukemia 8093; nilotinib; 3 day' vs 'pre-B acute lymphoblastic leukemia 8093; nilotinib; 0 day' | cell type, compound, time | Drug tolerance development of mouse Bcr/Abl pre-B ALL cells on irradiated MEFs |
1.4 | | Pax7 | 'Smad4 mutant' vs 'control' | genotype | Gene expression profile of Myf5-Cre;Smad4flox/flox mutant |
1.3 | | Pax7 | 'Men1-null' vs 'wild type' | genotype | Differentially regulated genes in adipocytes derived from Men1-null vs WT mouse embryonic stem cells |
-1.3 | | Pax7 | 'mir181a1/b1 Knockout' vs 'wild type' | genotype | Mouse CD4+/CD8+ thymocytes from miR-181a1/b1 KO vs WT |
1.2 | | Pax7 | 'postnatal >1 year; hindlimb' vs 'embryonic day 17.5; whole forelimb and hindlimb' | age, organism part | Expression data from skeletal muscle satellite cells at different development stages |
-1.2 | | Pax7 | '3110043O21Rik knockout; spleen' vs 'wild type genotype; spleen' | genotype, organism part, sampling site | RNAseq of coding RNA in the liver, spleen, kidney, abdominal muscle and gonadal adipose tissue of knock out mice and wild type controls. |
1.1 | | Pax7 | 'Double knockout (TNFR1-/-, TNFR2-/-)' vs 'wild type' | genotype | Transcription profiling by high throughput sequencing of douple (TNFR1-/-/TNFR2-/-) and triple (Zfp36-/-/TNFR1-/-/TNFR2-/-) knockout mouse spleens |
1.1 | | Pax7 | 'postnatal 2-3 month; hindlimb' vs 'embryonic day 17.5; whole forelimb and hindlimb' | age, organism part | Expression data from skeletal muscle satellite cells at different development stages |
-1.1 | | Pax7 | 'unilateral ureteral obstruction' vs 'sham' in 'TIMP3 -/-' | genotype, treatment | TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injury |
-1 | | Pax7 | 'bisphenol AF; 10 micromolar' vs 'vehicle' | compound | Transcriptomic analyses of 11.5 dpc female germ cell (mouse) exposed or not to Bisphenol A analogues (BPAF and BADGE) |
-1 | | Pax7 | 'pre-B acute lymphoblastic leukemia 8093; lonafarnib; 4 day' vs 'pre-B acute lymphoblastic leukemia 8093; lonafarnib; 0 day' | cell type, compound, time | Drug tolerance development of mouse Bcr/Abl pre-B ALL cells on irradiated MEFs |
-1 | | Pax7 | 'Wnt1Cre Ezh2lox/lox' vs 'control' | genotype | Expression data from E11.5 mouse branchial arch 1 (BA1) - comparison between Ezh2lox/lox and Wnt1Cre Ezh2lox/lox embryos |
1 | | Pax7 | 'shRNA p68/p72 knockdown; differentiated' vs 'control; differentiated' on 'Affymetrix Array MOE430B' | RNA interference, developmental stage | Transcription profiling of p68/72 deficient C2C12 cells to investigate the function of p68/p72 in muscle gene expression and skeletal C2C12 cell differentiation. |